A Phase 3 interventional study of REGN2810 and REGN2810/chemo/ipi in Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Completed at 133 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is one of 4 that started in 2018, is one of 5 in phase 3, and was the 2nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Georgetown University · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
UNICANCER · Sites in France
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Austria, Estonia, France and 6 more countries
Ages 18+
Maia Biotechnology · Sites in Poland, Romania, Taiwan and 1 more country
Ages 18+
By country, each count listing its studies:
cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 6
First in 2017; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 789 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 61 across the 29 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 29 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals: 2 open now, 11 under way, 2 of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2018, is one of 3 in phase 3, and was the 3rd registered.
Regeneron Pharmaceuticals’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2008.
3 of the studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06908304Phase 3Maia BiotechnologyA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | 2027-07-31 |
| NCT06088771Icahn School of Medicine at Mount SinaiNeoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | 2026-12-01 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Regeneron Pharmaceuticals’s 21 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are:
Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 in \<50% of tumor cells.
Part 2: To compare the OS of cemiplimab/chemo-f with placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression.
The key secondary objectives are:
Part 1: To compare the progression-free survival (PFS) and objective response rate (ORR) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC and tumors expressing PD-L1 in \<50% of tumor cells.
Part 2: To compare the PFS and ORR of cemiplimab/chemo-f versus placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Chemotherapy
Other: Chemotherapy · Drug: Placebo
Part 1: REGN2810+chemo
Drug: REGN2810
Part 1: REGN2810+abbrev chemo+ipi
Drug: REGN2810/chemo/ipi
Part 2: Placebo plus chemo
Drug: Placebo
Part 2: REGN2810+chemo
Drug: REGN2810
REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
Also known as: cemiplimab
Drug page: Cemiplimab
REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
Also known as: cemiplimab
Platinum-based doublet chemotherapy Part 1
Matching placebo Part 2
This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.
Part 1: Overall Survival (OS)
OS was defined as the time from randomization to the date of death due to any cause.
Time frame: Up to a maximum of 82.2 months
Part 2: OS
OS was defined as the time from randomization to the date of death due to any cause.
Time frame: Up to a maximum of 68.4 months
Part 1: Progression-free Survival (PFS) Per Independent Review Committee (IRC)
PFS as assessed by IRC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.
Time frame: Up to a maximum of 82.2 months
Part 2: PFS Per IRC
PFS as assessed by IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.
Time frame: Up to a maximum of 68.4 months
Part 1: Objective Response Rate (ORR) Per IRC
ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR).
Time frame: Up to 32 months
Part 2: ORR Per IRC
ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a BOR of confirmed CR or PR.
Time frame: Up to 32 months
Part 1: Duration of Response (DoR)
DoR was defined as the time from date of first documented response of CR or PR to the date of first documented progressive disease (PD) or death due to any cause, whichever occurred earlier.
Time frame: Up to 32 months
Part 2: DoR
DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD or death due to any cause, whichever occurred earlier.
Time frame: Up to 32 months
Part 1: Best Overall Response (BOR) Per IRC
BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.
Time frame: Up to 32 months
Part 2: BOR Per IRC
BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.
Time frame: Up to 32 months
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
Time frame: From first dose of study drug in Part 1, up to approximately 83 months
Part 2: Number of Participants With TEAEs
TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
Time frame: From first dose of study drug in Part 2, up to approximately 69 months
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Part 1 only
Time frame: 28 days
Part 1: Number of Participants With Serious TEAEs
Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
Time frame: From first dose of study drug in Part 1, up to approximately 83 months
Part 2: Number of Participants With Serious TEAEs
Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
Time frame: From first dose of study drug in Part 2, up to approximately 69 months
Part 1: Number of Deaths During the On-Treatment Period
The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.
Time frame: Up to 28 months
Part 2: Number of Deaths During the On-Treatment Period
The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.
Time frame: Up to 28 months
Part 1: Estimated Survival Probability
OS rate at a landmark (12, 18, and 24 months) was defined as the Kaplan-Meier (K-M) estimated probability of participants who survived due to any cause at the landmark after randomization.
Time frame: 12 months, 18 months, 24 months
Part 2: Estimated Survival Probability
OS rate at a landmark (12, 18, and 24 months) was defined as the K-M estimated probability of participants who survived due to any cause at the landmark after randomization.
Time frame: 12 months, 18 months, 24 months
Part 1: Change From Baseline in Global Health Status Score as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life (QoL) in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.
Time frame: Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 19, 20, 21, 22, 23, 24, 27, 30, 33, 36, 39, 40, 42, 45, 48, 51, 54, 57, 60, 63, 66; Follow-up visit 1 (14 to 30 days after last study treatment) then continued follow-up every 3 months
Part 2: Change From Baseline in Global Health Status Score as Measured by the EORTC QLQ-C30
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.
Time frame: Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36; Follow-up 1 (14 to 30 days after last study treatment)
| Milestone | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|---|---|---|
| Started | 108 | 109 | 106 | 312 | 154 |
| Randomized and treated | 108 | 109 | 103 | 312 | 153 |
| Completed treatment | 10 | 18 | 53 | 70 | 2 |
| Completed | 10 | 9 | 9 | 31 | 4 |
| Not completed | 98 | 100 | 97 | 281 | 150 |
| Withdrew: Adverse event | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Death | 40 | 32 | 34 | 83 | 42 |
| Withdrew: Lost to follow-up | 2 | 2 | 2 | 9 | 3 |
| Withdrew: Participant decision | 9 | 4 | 9 | 25 | 21 |
| Withdrew: Sponsor decision | 4 | 0 | 0 | 5 | 0 |
| Withdrew: Physician decision | 0 | 1 | 2 | 4 | 1 |
| Withdrew: Disease progression | 34 | 49 | 36 | 132 | 76 |
| Withdrew: Withdrawal of consent | 9 | 7 | 10 | 14 | 7 |
| Withdrew: Other than specified | 0 | 5 | 2 | 7 | 0 |
| Withdrew: Non-compliance with study drug(s) | 0 | 0 | 0 | 1 | 0 |
PFS as assessed by IRC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.
| months | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Part 1: Progression-free Survival (PFS) Per Independent Review Committee (IRC) | 6.5 (6.2 to 8.3) | 6.4 (4.2 to 8.4) | 6.4 (5.9 to 7.2) |
PFS as assessed by IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.
| months | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| Part 2: PFS Per IRC | 8.2 (6.5 to 9.0) | 5.5 (4.3 to 6.2) |
ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR).
| Percentage of participants | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Part 1: Objective Response Rate (ORR) Per IRC | 40.7 (31.4 to 50.6) | 36.7 (27.7 to 46.5) | 28.3 (20.0 to 37.9) |
ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a BOR of confirmed CR or PR.
| Percentage of participants | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| Part 2: ORR Per IRC | 43.6 (38.0 to 49.3) | 22.1 (15.8 to 29.5) |
DoR was defined as the time from date of first documented response of CR or PR to the date of first documented progressive disease (PD) or death due to any cause, whichever occurred earlier.
| months | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Part 1: Duration of Response (DoR) | 7.8 (6.2 to 13.2) | 15.9 (8.7 to 35.1) | 6.2 (5.2 to 10.4) |
DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD or death due to any cause, whichever occurred earlier.
| months | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| Part 2: DoR | 16.4 (13.1 to 19.5) | 7.3 (4.2 to 11.3) |
BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.
| Participants | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Complete Response (CR) | 3 | 5 | 2 |
| Partial Response (PR) | 41 | 35 | 28 |
| Stable Disease (SD) | 41 | 44 | 51 |
| Progressive Disease (PD) | 4 | 15 | 8 |
| Non-CR / Non-PD | 3 | 0 | 1 |
| Not Evaluable (NE) | 16 | 10 | 16 |
BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.
| Participants | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| CR | 20 | 0 |
| PR | 116 | 34 |
| SD | 121 | 75 |
| PD | 22 | 24 |
| Non-CR/Non-PD | 3 | 1 |
| NE | 30 | 20 |
TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
| Participants | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 105 | 104 | 99 |
TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
| Participants | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| Part 2: Number of Participants With TEAEs | 301 | 145 |
Part 1 only
| Participants | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Part 1: Number of Participants With Dose-limiting Toxicities (DLTs) | — | 0 | — |
Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
| Participants | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Part 1: Number of Participants With Serious TEAEs | 37 | 37 | 22 |
Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
| Participants | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| Part 2: Number of Participants With Serious TEAEs | 95 | 37 |
The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.
| Participants | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Part 1: Number of Deaths During the On-Treatment Period | 36 | 24 | 18 |
The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.
| Participants | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| Part 2: Number of Deaths During the On-Treatment Period | 85 | 39 |
OS rate at a landmark (12, 18, and 24 months) was defined as the Kaplan-Meier (K-M) estimated probability of participants who survived due to any cause at the landmark after randomization.
| Estimated percentage of participants | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| 12 months | 59.4 (48.9 to 68.4) | 68.5 (58.4 to 76.6) | 54.0 (43.6 to 63.3) |
| 18 months | 47.5 (37.2 to 57.1) | 51.9 (41.7 to 61.2) | 39.7 (29.8 to 49.4) |
| 24 months | 41.0 (31.1 to 50.7) | 42.3 (32.4 to 51.9) | 26.5 (18.0 to 35.7) |
OS rate at a landmark (12, 18, and 24 months) was defined as the K-M estimated probability of participants who survived due to any cause at the landmark after randomization.
| Estimated percentage of participants | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| 12 months | 66.4 (60.8 to 71.5) | 53.9 (45.4 to 61.6) |
| 18 months | 53.7 (47.8 to 59.2) | 35.8 (28.0 to 43.7) |
| 24 months | 43.9 (38.2 to 49.5) | 27.7 (20.5 to 35.3) |
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life (QoL) in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.
| Score on a Scale | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Cycle 2, Day 1 (C2D1) | 2.13 ± 17.237 | 1.58 ± 15.154 | 0.92 ± 14.930 |
| C3D1 | 4.65 ± 16.598 | 2.75 ± 18.310 | 2.16 ± 16.525 |
| C4D1 | 6.22 ± 16.505 | 3.00 ± 20.383 | 2.67 ± 17.446 |
| C5D1 | 3.31 ± 19.385 | 4.72 ± 18.414 | 0.32 ± 18.957 |
| C6D1 | 5.63 ± 19.302 | 3.38 ± 19.356 | -1.70 ± 20.552 |
| C9D1 | 6.87 ± 17.965 | 1.80 ± 22.005 | -3.79 ± 16.399 |
| C12D1 | 4.44 ± 22.019 | 9.15 ± 20.650 | -3.57 ± 13.486 |
| C15D1 | 7.35 ± 24.769 | 9.40 ± 19.325 | -5.56 ± 13.608 |
| C18D1 | 6.73 ± 25.606 | 14.44 ± 20.983 | -3.33 ± 13.944 |
| C19D1 | 22.62 ± 20.250 | 4.17 ± 18.898 | -16.67 ± 0.000 |
| C20D1 | 13.89 ± 26.176 | 9.52 ± 12.199 | -16.67 ± 0.000 |
| C21D1 | 11.36 ± 24.336 | 15.71 ± 20.592 | 0.00 ± 13.608 |
| C22D1 | 20.00 ± 29.226 | 5.95 ± 9.272 | -16.67 |
| C23D1 | 11.67 ± 26.745 | 12.50 ± 4.811 | -8.33 ± 11.785 |
| C24D1 | 8.33 ± 26.040 | 14.29 ± 23.295 | -11.11 ± 9.623 |
| C27D1 | 8.89 ± 24.694 | 19.05 ± 18.285 | -22.22 ± 41.944 |
| C30D1 | 10.94 ± 25.408 | 13.64 ± 17.918 | -5.56 ± 19.245 |
| C33D1 | 12.82 ± 19.429 | 14.17 ± 17.543 | 0.00 ± 23.570 |
| C36D1 | 12.50 ± 22.713 | 13.24 ± 17.936 | 16.67 |
| C39D1 | 50.00 | — | 16.67 |
| C40D1 | 50.00 | — | — |
| C42D1 | 50.00 | — | 16.67 |
| C45D1 | 50.00 | — | — |
| C48D1 | 50.00 | — | — |
| C51D1 | 50.00 | — | — |
| C54D1 | 33.33 | — | — |
| C57D1 | 33.33 | — | — |
| C60D1 | 33.33 | — | — |
| C63D1 | 33.33 | — | — |
| C66D1 | 41.67 | — | — |
| Follow-up 1 | 4.05 ± 18.455 | 3.14 ± 21.260 | 3.87 ± 20.839 |
| Follow-up 2 | 8.33 ± 11.785 | 33.33 | 3.21 ± 22.704 |
| Follow-up 3 | -8.33 | — | 4.17 ± 5.893 |
OS was defined as the time from randomization to the date of death due to any cause.
| months | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy |
|---|---|---|---|
| Part 1: Overall Survival (OS) | 15.9 (11.7 to 24.2) | 20.1 (13.7 to 28.3) | 13.9 (10.0 to 17.7) |
OS was defined as the time from randomization to the date of death due to any cause.
| months | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| Part 2: OS | 21.1 (15.9 to 23.9) | 12.9 (10.6 to 16.1) |
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.
| Score on a Scale | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|
| C2D1 | 0.31 ± 17.199 | 1.50 ± 18.190 |
| C3D1 | 0.96 ± 17.175 | 2.80 ± 17.098 |
| C4D1 | 1.92 ± 19.293 | 4.09 ± 18.592 |
| C5D1 | 3.35 ± 18.912 | 2.28 ± 21.686 |
| C6D1 | 3.42 ± 19.649 | 2.89 ± 19.452 |
| C9D1 | 3.65 ± 19.657 | 2.02 ± 21.236 |
| C12D1 | 2.37 ± 19.056 | 3.54 ± 23.862 |
| C15D1 | 6.23 ± 18.090 | 6.61 ± 22.091 |
| C18D1 | 5.28 ± 21.578 | 10.09 ± 22.323 |
| C21D1 | 6.07 ± 21.340 | 18.59 ± 22.088 |
| C24D1 | 5.05 ± 20.347 | 10.83 ± 25.474 |
| C27D1 | 5.27 ± 21.905 | 8.33 ± 27.003 |
| C30D1 | 6.82 ± 19.947 | 4.17 ± 45.896 |
| C33D1 | 4.56 ± 20.518 | 27.78 ± 25.459 |
| C36D1 | 6.94 ± 21.363 | 41.67 ± 11.785 |
| Follow-up 1 | -2.70 ± 21.826 | -0.99 ± 23.422 |
Collected over From the time the informed consent was signed, up to approximately 83 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cemiplimab + Chemotherapy | 84/108 (77.8%) | 38/108 (35.2%) | 102/108 (94.4%) |
| Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | 80/109 (73.4%) | 39/109 (35.8%) | 97/109 (89%) |
| Part 1: Chemotherapy | 80/103 (77.7%) | 23/103 (22.3%) | 94/103 (91.3%) |
| Part 1: Chemotherapy to Cemiplimab | 7/31 (22.6%) | 7/31 (22.6%) | 19/31 (61.3%) |
| Part 2: Cemiplimab + Chemotherapy | 232/312 (74.4%) | 95/312 (30.4%) | 288/312 (92.3%) |
| Part 2: Placebo + Chemotherapy | 129/153 (84.3%) | 38/153 (24.8%) | 136/153 (88.9%) |
| Event | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy | Part 1: Chemotherapy to Cemiplimab | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 8/108 | 3/109 | 2/103 | 1/31 | 9/312 | 4/153 |
| DeathGeneral disorders | 2/108 | 0/109 | 5/103 | 0/31 | 9/312 | 2/153 |
| AnaemiaBlood and lymphatic system disorders | 3/108 | 4/109 | 4/103 | 0/31 | 9/312 | 3/153 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/108 | 4/109 | 0/103 | 0/31 | 5/312 | 2/153 |
| Urinary tract infectionInfections and infestations | 0/108 | 1/109 | 0/103 | 1/31 | 1/312 | 1/153 |
| HaematemesisGastrointestinal disorders | 0/108 | 0/109 | 0/103 | 1/31 | 0/312 | 0/153 |
| Cerebrovascular accidentNervous system disorders | 0/108 | 0/109 | 2/103 | 1/31 | 1/312 | 0/153 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/108 | 0/109 | 0/103 | 1/31 | 0/312 | 0/153 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/108 | 2/109 | 0/103 | 1/31 | 0/312 | 0/153 |
| Immune-mediated hepatitisHepatobiliary disorders | 0/108 | 0/109 | 0/103 | 1/31 | 0/312 | 0/153 |
| Event | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy | Part 1: Chemotherapy to Cemiplimab | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 52/108 | 37/109 | 39/103 | 6/31 | 138/312 | 61/153 |
| AlopeciaSkin and subcutaneous tissue disorders | 30/108 | 22/109 | 33/103 | 0/31 | 117/312 | 67/153 |
| NauseaGastrointestinal disorders | 25/108 | 31/109 | 31/103 | 1/31 | 79/312 | 25/153 |
| NeutropeniaBlood and lymphatic system disorders | 31/108 | 18/109 | 27/103 | 0/31 | 47/312 | 19/153 |
| AstheniaGeneral disorders | 24/108 | 21/109 | 14/103 | 1/31 | 41/312 | 17/153 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 23/108 | 20/109 | 16/103 | 2/31 | 54/312 | 21/153 |
| FatigueGeneral disorders | 13/108 | 23/109 | 16/103 | 1/31 | 46/312 | 13/153 |
| Decreased appetiteMetabolism and nutrition disorders | 22/108 | 17/109 | 17/103 | 1/31 | 56/312 | 20/153 |
| HyperglycaemiaMetabolism and nutrition disorders | 9/108 | 6/109 | 7/103 | 0/31 | 58/312 | 18/153 |
| ThrombocytopeniaBlood and lymphatic system disorders | 20/108 | 10/109 | 14/103 | 0/31 | 43/312 | 19/153 |
Full Analysis Set (FAS) included all participants to whom study treatment had been assigned by randomization in each study part.
| Age, Continuous(Years) | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| Median | 63.0 (32 to 87) | 64.0 (39 to 85) | 63.0 (40 to 81) | 63.0 (25 to 82) | 63.0 (34 to 84) | 63.0 (25 to 87) |
| Sex: Female, Male(Participants) | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| Female | 21 | 16 | 13 | 44 | 31 | 125 |
| Male | 87 | 93 | 93 | 268 | 123 | 664 |
| Race/Ethnicity, Customized(Participants) | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| White | 91 | 97 | 91 | 267 | 138 | 684 |
| Asian | 12 | 6 | 7 | 45 | 16 | 86 |
| Not reported | 0 | 2 | 0 | 0 | 0 | 2 |
| Missing | 5 | 4 | 8 | 0 | 0 | 17 |
| Race/Ethnicity, Customized(Participants) | Part 1: Cemiplimab + Chemotherapy | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | Part 1: Chemotherapy | Part 2: Cemiplimab + Chemotherapy | Part 2: Placebo + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 101 | 104 | 98 | 311 | 149 | 763 |
| Not reported | 0 | 1 | 0 | 1 | 5 | 7 |
| Missing | 5 | 4 | 8 | 0 | 0 | 17 |
Showing the first 100 of 133 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Feb 2025, 83 months.
Results were first posted in Apr 2026, 1 year 2 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 83 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab
Carcinoma, Non-Small-Cell Lung →